BG 00012

Known as: 00012, BG, BG-00012, BG00012 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2007-2012
01220072012

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Baseline disease-modifying therapies (DMTs) for multiple sclerosis (MS) include three different preparations of interferon-beta… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Inflammation and oxidative stress are thought to promote tissue damage in multiple sclerosis. Thus, novel therapeutics enhancing… (More)
Is this relevant?
Review
2010
Review
2010
IMPORTANCE OF THE FIELD One of the disadvantages of currently available disease-modifying drugs (DMDs) for multiple sclerosis (MS… (More)
Is this relevant?
Review
2010
Review
2010
Interferon beta was the first specific disease-modifying therapy licensed for multiple sclerosis (MS) and in its many forms… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND Oral fumarate (BG00012) might have dual anti-inflammatory and neuroprotective effects. Our aim was to assess the… (More)
Is this relevant?
Review
2007
Review
2007
Biogen Idec Inc, following its acquisition of Fumapharm AG, is developing BG-12 (Panaclar, BG-00012, FAG-201), an oral second… (More)
Is this relevant?